HOME >> MEDICINE >> NEWS
Alzheimer's pathology reduced, longevity improved in mouse model, Gladstone study shows

Removal of an enzyme that regulates the activity of many proteins can suppress key features of Alzheimer's disease in experimental models, researchers at the Gladstone Institute of Neurological Disease (GIND) recently reported in the Journal of Neuroscience (May 12, 2004).

Using well-established mouse models of Alzheimer's disease, the investigators examined how changing levels of the enzyme Fyn affects key aspects of the disease, including accumulation of large clumps of amyloid proteins in the brain (so-called plaques) and changes in the complex neuronal networks in which memories are formed and stored. Genetic engineering strategies were used to increase or decrease the expression of Fyn, which regulates many other proteins through the attachment of specific groups of atoms known as phosphate groups.

The researchers determined that changing levels of Fyn had no effect on plaque formation or aberrant sprouting (the abnormal growth of nerve terminals, in which neuchemical messages are stored), indicating that these pathologies involve discrete molecular mechanisms. However, they observed that blocking Fyn expression prevented amyloid proteins from damaging synapses, the specialized connections between brain cells, and improved the longevity of mice. (Experimental mice with Alzheimer's-like disease otherwise die prematurely.) In contrast, increasing Fyn in the brain worsened synaptic damage, and also increased the number of premature deaths in the mice.

Loss of synapses and abnormal outgrowth of nerve terminals occur both in people with Alzheimer's disease and in transgenic mice producing human amyloid proteins in the brain (the model used in the study). Humans with the disease, like mice, die prematurely.

"Synaptic degeneration in Alzheimer's disease is like electrical circuits in a computer becoming faulty -- signals can no longer be transmitted through broken connections," says senior author and GIND director Lennart Mucke, MD, who
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-476-2557
University of California - San Francisco
19-May-2004


Page: 1 2

Related medicine news :

1. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
2. Neuronal death and processing of Tau protein in Alzheimers disease
3. Researchers discover link between insulin and Alzheimers
4. New trials for counseling caregivers and patients with Alzheimers begin
5. Marijuana ingredient may stall decline from Alzheimers
6. Drugs used to treat Alzheimers in nursing homes are worsening sufferers illness
7. UT Southwestern doctors track Oklahoma Alzheimers patients via telemedicine
8. Contrary to previous findings, smoking is detrimental to patients with Alzheimers
9. Nanoscale diagnostic sets sights on Alzheimers
10. New test is first step in early detection of Alzheimers disease
11. Older people with the Alzheimers gene find it harder to remember to remember even if healthy

Post Your Comments:
(Date:7/30/2015)... ... 2015 , ... In an effort to provide the twenty four hour continuous ... in his practice. , The decision will also allow him to spend more time ... transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ... takes a look at small, medium, and large businesses making an impact in ... the business review and shared with viewers how DevExpress has provided software development ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Institute Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce the ... on the front lines and throughout the experience movement, and provide information and ...
(Date:7/30/2015)... Beach, California (PRWEB) , ... July 30, 2015 ... ... and services, announced today that the latest issue of Inclusive™ magazine, its multimedia ... digital platforms. The digital edition of the new issue, Volume 6, Issue 2, ...
Breaking Medicine News(10 mins):Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... -- Big Cloud Analytics, Inc. (BCA), a leading provider ... working with Intel Corporation to showcase Internet of ... Healthcare Technology Alliance. The recently formed alliance is ... technology companies and academic institutions. Its purpose is ... in rapidly evolving and growing areas of health ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
Cached News: